Arrowhead Pharmaceuticals/$ARWR

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Ticker

$ARWR
Primary listing

Industry

Biotechnology

Employees

609

ISIN

US04280A1007

ARWR Metrics

BasicAdvanced
$2.3B
-
-$1.14
0.90
-

What the Analysts think about ARWR

Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.

Bulls say / Bears say

Arrowhead Pharmaceuticals received a $30 million milestone payment from GSK following the initiation of a Phase 2b trial for GSK4532990, an RNAi therapeutic for NASH, indicating progress in their pipeline and potential future revenue streams. (stocktitan.net)
The company announced a $500 million strategic financing facility with Sixth Street, providing significant non-dilutive capital to fund innovation and growth opportunities across its RNAi therapeutics pipeline. (finance.yahoo.com)
Arrowhead Pharmaceuticals completed enrollment in multiple Phase 3 studies of plozasiran, demonstrating progress in their clinical development pipeline and potential for future product approvals. (stockanalysis.com)
The company's revenue decreased by 98.52% in 2024 compared to the previous year, reporting a loss of $599.49 million, raising concerns about financial stability. (stockanalysis.com)
Insider selling activity, including the CEO selling $567,485 in stock, may signal lack of confidence in the company's near-term prospects. (investing.com)
Analysts have lowered their price targets for Arrowhead Pharmaceuticals, with Sanford C. Bernstein reducing expectations from $27.00 to $24.00, reflecting diminished confidence in the stock's future performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

ARWR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ARWR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARWR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs